SCHEMBL1958883

SCHEMBL1958883

Cc1c(O)c(C(=O)O)c(=O)n(Cc2ccccc2)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 5/20 0.53
FEN1 P39748 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 1/20 0.53
TSHR P16473 1/20 0.53
POLB P06746 1/20 0.51
FABP4 P15090 1/20 0.50
NOTUM Q6P988 1/20 0.49
EGLN1 Q9GZT9 1/20 0.47
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
CYP2D6 P10635 1/20 0.46
PKM P14618 2/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.44
AR P10275 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1960754 0.83 EGLN1 (0.71) EGLN1KDM4E
SCHEMBL217059 0.78 KMT2A (0.47) SMN1; SMN2LMNATSHRFABP4HTT
SCHEMBL3350444 0.78 SMN1; SMN2 (0.58) SMN1; SMN2LMNATSHRPOLBFABP4
SCHEMBL11488105 0.76 CNR1 (0.47) ERCC5FEN1SMN1; SMN2LMNATSHR
SCHEMBL27724198 0.75 ERCC5 (0.61) ERCC5FEN1SMN1; SMN2LMNATSHR
SCHEMBL11609712 0.75 NOTUM (0.57) ERCC5FEN1SMN1; SMN2LMNATSHR
SCHEMBL13401691 0.73 SMN1; SMN2 (0.56) SMN1; SMN2LMNATSHRPOLBNOTUM
SCHEMBL612585 0.73 POLB (0.62) SMN1; SMN2LMNATSHRPOLBFABP4
SCHEMBL5574170 0.72 CNR2 (0.48) ERCC5FEN1LMNATSHREGLN1
SCHEMBL27703560 0.72 FEN1 (0.59) ERCC5FEN1EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144167-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144167-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 ERCC5 3011/4885FEN1 1383/4885SMN1; SMN2 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.